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Objectives. The purpose of this study was to assess whether the
presence or absence of myocardial viability during dobutamine
echocardiography (DE) predicts survival in patients with coro-
nary artery disease (CAD) and severe left ventricular (LV)
dysfunction.
Background. In patients with CAD, the presence of myocardial
viability during DE identifies viable myocardium and predicts
recovery of LV systolic function after revascularization. However,
there is little data on the relation between myocardial viability and
clinical outcome in patients with CAD and severe LV dysfunction.
Methods. We studied 318 patients with CAD and a LV ejection
fraction (EF) <235% who underwent DE and were followed for
18 6 10 months. Patients were classified into four groups. Group
I (n 5 85) consisted of patients who had evidence of myocardial
viability and subsequently underwent revascularization. Group II
(n 5 119) consisted of patients with myocardial viability who did
not undergo revascularization. Group III (n 5 30) consisted of
patients who did not have myocardial viability and underwent
revascularization. Finally, group IV (n 5 84) patients lacked
myocardial viability and did not undergo revascularization.
Results. The four groups had similar baseline characteristics
and rest LVEF. During follow-up there were 51 deaths (16%). The
mortality rate was 6% in group I, 20% in group II, 17% in group
III and 20% in group IV (p 5 0.01, group I vs. other groups).
Conclusions. In patients with CAD and severe LV dysfunction
who demonstrated myocardial viability during DE, revasculariza-
tion improved survival compared with medical therapy.
(J Am Coll Cardiol 1998;32:921–6)
©1998 by the American College of Cardiology
Left ventricular (LV) function is a major determinant of
survival in patients with coronary artery disease (CAD) (1).
Patients with severe LV systolic dysfunction (LV ejection
fraction [EF] ,35%) have particularly high mortality (2–4). It
is now well recognized that ventricular dysfunction in some
patients with severe CAD may be due to viable, hibernating
myocardium rather than irreversible scar (5,6). If ventricular
dysfunction is due to hibernation, myocardial contractility
frequently improves after revascularization (7–11). Assessment
of myocardial viability is increasingly being used to decide
whether patients with CAD and severe LV dysfunction should
undergo revascularization (12–15). Several studies have shown
that myocardial viability during dobutamine echocardiography
(DE) accurately predicts recovery of rest LV function after
revascularization (10,16–20). However, there is little data on
the relation between myocardial viability and clinical outcome
in patients treated medically or with revascularization. The
purpose of this study was to assess whether the presence or
absence of myocardial viability during DE predicts survival in
patients with CAD and severe LV dysfunction.
Methods
Study patients. The study group was selected from patients
evaluated and managed at the participating institutions who
underwent DE between 1993 and 1996 and met the following
criteria: 1) presence of CAD, defined as $70% stenosis in at
least one major epicardial coronary artery; and 2) rest LVEF
#35% determined visually by two-dimensional echocardiogra-
phy. Patients with recent myocardial infarction (,1 month)
were excluded.
Dobutamine echocardiography. Patients underwent DE
according to the local protocol at each institution. The starting
dobutamine dose was 2.5 mg/kg/body weight per min in 106
patients and 5 mg/kg per min in 212 patients. Incremental
dobutamine doses were then given at either 3-min (n 5 266) or
5-min (n 5 52) intervals. The majority of patients (79%) were
studied using a full dose protocol (dobutamine doses up to
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40 mg/kg per min and atropine if the heart rate was ,85% of
predicted maximal), while the remaining patients underwent a
low dose study (dobutamine doses up to 20 mg/kg per min).
Differences in DE protocols reflect clinical practice, as there is
no “standard” dobutamine protocol for viability assessment.
The data on DE were obtained from an interpretation per-
formed at each center at the time of the study. Altogether
there were 20 experienced echocardiographers who inter-
preted these studies. For analysis, the LV was divided into the
standard 16-segment model as recommended by the American
Society of Echocardiography (21). Wall motion at rest was
scored using a 4-grade scoring system (1 5 normal; 2 5
hypokinesia; 3 5 akinesia; 4 5 dyskinesia). The rest wall
motion score index was calculated as the sum of segmental wall
motion scores divided by the number of scored segments. For
each segment with abnormal rest wall motion, the response to
low dose and peak dose dobutamine was assessed and classi-
fied as sustained improvement, worsening, biphasic or no
change (10). Although there were differences in DE protocols,
all centers used 5- and 10-mg/kg per min doses to assess the
wall motion response to low dose dobutamine. A patient was
considered to have myocardial viability if four or more seg-
ments demonstrated improvement, worsening or a biphasic
response during DE. We chose this definition based on previ-
ous studies demonstrating that evidence of viability in four or
more segments during DE is associated with a significant
improvement in LVEF after revascularization (20,22).
Clinical data. Baseline demographic and clinical data on
the study patients were collected at each site at the time of DE.
Follow-up survival data were obtained by chart review, from
patients’ physicians or by telephone contact with the patients,
or a combination of these. The end point of the study was total
mortality.
Statistical analysis. All data are reported as the mean
value 6 SD. The characteristics of the patient groups were
compared by using analysis of variance and the chi-square test.
Statistical significance was set at p , 0.05. Patient groups were
compared for nominal variables using the Bonferroni correc-
tion, and p , 0.01 was required for statistical significance.
Differences in survival between patient groups were compared
using Kaplan-Meier survival curves, and statistical significance
was determined by the log-rank test. Independent predictors of
mortality were identified by Cox proportional hazards analysis.
Results
Patient group. Study selection criteria were met by 353
patients. Follow-up data could not be obtained in 35 patients
(10%). Thus, the final study group consisted of 318 patients
(79% men, mean age 64 6 11 years). The rest LVEF was 27 6
7%, and 54% of patients had three-vessel CAD.
Results of DE. The reasons for performing DE in the study
patients are listed in Table 1. DE demonstrated myocardial
viability in 204 patients (64%). Patients with and without
myocardial viability had a similar rest LVEF (27 6 7% vs. 28 6
6%, p 5 0.6) and wall motion score index (2.3 6 0.4 vs. 2.2 6
0.4, p 5 0.2). Among patients with myocardial viability, 3,203
segments were visualized and 2,762 (86%) had abnormal wall
motion at rest. During DE sustained improvement was seen in
943 segments (34%), worsening in 300 (11%), a biphasic
response in 291 (10%) and no change in wall motion in 1,228
(45%). Among patients without myocardial viability, 1,793
segments were visualized and 1,372 (77%) had an abnormal
wall motion at rest. During DE, sustained improvement was
seen in 100 segments (7%), worsening in 43 (3%), a biphasic
response in 18 (1%) and no change in wall motion in 1,211
(88%).
Patient groups. Within 3 months after DE, 115 patients
(36%) underwent coronary revascularization either by coro-
nary artery bypass graft surgery (n 5 79) or percutaneous
transluminal coronary angioplasty (n 5 36). The decision for
revascularization was not randomized and was made by the
patients’ physicians. Based on DE findings and revasculariza-
tion status, patients were classified into four groups. Group I
consisted of 85 patients with myocardial viability during DE
who subsequently underwent revascularization. Group II con-
sisted of 119 patients with myocardial viability who did not
undergo revascularization. Group III consisted of 30 patients
who did not have myocardial viability and underwent revascu-
larization. Group IV patients (n 5 84) lacked myocardial
viability and were not revascularized. Table 2 compares the
clinical, angiographic and rest echocardiographic findings in
the four groups. Patients in group III were younger, with a
higher rest LVEF.
Mortality. Among 318 patients followed for 18 6 10
months, there were 51 deaths (16%). Figure 1 shows survival in
the four groups over time. Differences in survival between
patients in group I and the other three groups increased over
time (99% vs. 94% at 6 months, 96% vs. 89% at 12 months,
92% vs. 83% at 18 months and 92% vs. 78% at 2 years, p 5
0.01). Among revascularized patients, mortality was similar
between those treated by bypass surgery and coronary angio-
plasty (8% vs. 11%, p 5 NS).
Independent predictors of mortality. To assess the value of
myocardial viability compared with known predictors of out-
Abbreviations and Acronyms
CAD 5 coronary artery disease
DE 5 dobutamine echocardiography
EF 5 ejection fraction
LV 5 left ventricular
Table 1. Indications for Dobutamine Echocardiography
Indication n (%)
Detection of myocardial viability 169 (53)
Evaluation of known CAD 76 (24)
Evaluation of suspected CAD 73 (23)
CAD 5 coronary artery disease.
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come in patients with CAD, Cox multivariate analysis was done
(Table 3). After adjustment for age, LV function and severity
of CAD, the absence of the group I characteristic (myocardial
viability during DE followed by revascularization) remained an
independent predictor of mortality. Age and LVEF predicted
mortality only in patients who were not revascularized. Among
nonrevascularized patients, age and LVEF were 64 1 11 years
and 28 1 7%, respectively, in survivors, compared with 69 1 9
years and 24 1 7%, respectively, in nonsurvivors (p 5 0.01 for
age and p 5 0.001 for LVEF). Among revascularized patients,
age and LVEF were similar between survivors and nonsurvi-
vors (age 62 1 10 years vs. 63 1 10 years, p 5 0.9; LVEF 28 1
7% vs. 29 1 8%, p 5 0.8). In revascularized patients the only
significant predictor of mortality was the absence of myocardial
viability (Table 4).
Discussion
Our study demonstrated that in patients with CAD and
severe LV systolic dysfunction who had evidence of myocardial
viability on DE, revascularization improved survival compared
with medical therapy. In the absence of myocardial viability,
mortality was similar in patients who did and did not undergo
revascularization.
Rationale for myocardial viability testing. Patients with
CAD and LV dysfunction have high mortality and morbidity
and consume substantial health care resources owing to fre-
quent hospital admissions for congestive heart failure, arrhyth-
mias and recurrent ischemiam (2–4). The prevalence of heart
failure, in particular, is increasing at an alarming rate, with the
estimated treatment cost in the United States being over 10
billion dollars each year (4). Because ischemic LV dysfunction
is the most common cause of heart failure, one can readily
recognize the importance of proper management of this group
of patients. Large trials comparing medical and surgical ther-
apy for CAD have excluded patients with a LVEF ,35% (23).
In fact, surgical treatment has been considered contraindicated
in such patients in the past (24). Recently, with improvements
in surgical technique and better myocardial preservation, it has
been shown that bypass surgery may be performed with
acceptable mortality, even in patients with severe ventricular
dysfunction (7,25). Observations from the Coronary Artery
Surgery Study registry suggest that, compared with medical
therapy, revascularization may improve survival in patients
with severe LV dysfunction (26). However, both initial opera-
tive mortality and overall long-term absolute mortality were
significantly higher in patients with a lower LVEF (26). Thus,
identification of subsets of patients with CAD and LV dysfunc-
tion who benefit the most from revascularization is important
to optimize patient outcome and utilization of health care
resources. The presence of myocardial viability has been shown
to predict improvement in LV function after coronary revas-
cularization (9–11). Several modalities have been investigated
Figure 1. Comparison of Kaplan-Meier survival survival curves in the
four patient groups.
Table 3. Independent Predictors of Mortality
Variable Risk Ratio (95% CI) p Value
LVEF 0.93 (0.90–0.98) 0.002
Age 1.03 (1.0–1.06) 0.01
Nongroup I patients 1.65 (1.06–2.82) 0.02
Three-vessel CAD 1.22 (0.81–1.80) 0.6
CI 5 confidence interval; other abbreviations as in Table 2.
Table 4. Independent Predictors of Mortality in
Revascularized Patients
Variable Risk Ratio (95% CI) p Value
Age 1.03 (0.96–1.10) 0.4
Three-vessel CAD 0.6 (0.16–2.0) 0.4
LVEF 0.98 (0.90–1.10) 0.8
Nongroup I patients 3.6 (1.0–13.0) 0.05
Abbreviations as in Tables 2 and 3.
Table 2. Comparison of Baseline Characteristics of Patient Groups
Characteristic
Group I
(n 5 85)
Group II
(n 5 119)
Group III
(n 5 30)
Group IV
(n 5 84)
Age (years) 63 6 10 65 6 11 60 6 9 65 6 11
DM 24% 27% 27% 21%
Previous MI 57% 61% 67% 57%
CHF 59% 56% 60% 56%
Angina 54%† 32% 43% 20%
Previous CABG 25% 28% 13% 21%
Beta-blocker use 17% 18% 37% 22%
Q waves on ECG‡ 44% 40% 55% 50%
Three-vessel CAD 39% 49% 41% 54%
Rest WMSI 2.3 6 0.4 2.3 6 0.4 2.1 6 0.4 2.2 6 0.4
Rest LVEF 27 6 6% 26 6 7% 30 6 7%* 27 6 8%
CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery
disease; CHF 5 congestive heart failure; DM 5 diabetes mellitus; ECG 5
electrocardiogram; LVEF 5 left ventricular ejection fraction; MI 5 myocardial
infarction; WMSI 5 wall motion score index. *p , 0.05 compared with all other
groups. †p , 0.01 compared with group IV. ‡Only patients with interpretable
electrocardiograms. Data are presented as the mean value 6 SD or percentage
of patients.
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for the identification of viable myocardium before revascular-
ization. These have included methods assessing perfusion and
metabolic activity with positron emission tomography or radio-
nuclide techniques and those demonstrating myocardial viabil-
ity during DE (9–11,27,28). Considerable resources are spent
on “viability testing” and some patients are denied revascular-
ization owing to a lack of myocardial viability (12). However, it
remains unclear whether testing for myocardial viability has an
impact on outcome of coronary revascularization.
Owing to low cost, portability and wide availability, DE is
particularly attractive for the assessment of myocardial viabil-
ity. We and other investigators have shown that the response of
the dysfunctional myocardium to dobutamine is a strong
predictor of recovery of contractile function after revascular-
ization (10,16–18). More recently, comparative studies be-
tween DE and thallium-201 scintigraphy have demonstrated
that myocardial viability on DE is more specific for prediction
of recovery of function than myocardial thallium uptake
(28,29). Previously, no study has assessed whether preopera-
tive assessment of myocardial viability by DE predicts clinical
outcome after revascularization.
Myocardial viability and prognosis. This is the largest
study to date on the prognostic value of myocardial viability in
patients with CAD and severe LV dysfunction. We studied the
impact of viable myocardium on outcome both with and
without revascularization. Patients with myocardial viability
who were revascularized had significantly improved survival
compared with those who were not revascularized. The prog-
nostic value of myocardial viability was independent of known
indicators of outcome, including age, LV function and severity
of CAD. An interesting observation was that the difference in
survival between group I and II patients did not become
evident until several months after revascularization. Partly, this
may reflect initial surgical mortality in group I. In addition,
viable, hibernating myocardium may demonstrate persistent
LV dysfunction immediately after revascularization owing to
concomitant stunning after restoration of coronary blood flow
(30). Recovery of LV function after revascularization is often
slow and may take weeks to months (10,30–32).
There are several potential mechanisms by which revascu-
larization may improve survival in patients with viable myocar-
dium. Revascularization of viable myocardium improves rest
LV function, which is a powerful determinant of prognosis
(6,7,23). Even if rest function does not improve, we have shown
that revascularization enhances cardiac reserve in patients with
preoperative evidence of myocardial viability (30). Patients
with severe CAD and viable myocardium have a high incidence
of ischemic events with medical therapy, which may further
reduce LV function or precipitate fatal arrhythmias (33). By
relieving ischemia, revascularization may prevent a further
decline in LV function and reduce arrhythmogenicity
(8,34,35). In addition, revascularization may have a favorable
impact on ventricular remodeling, a known marker of adverse
outcome (8).
An important finding of our study was that revasculariza-
tion did not improve survival in patients without preoperative
evidence of myocardial viability. The finding is suggestive but
not conclusive, because only a small number of patients
without myocardial viability underwent revascularization.
However, these patients were younger and had better LV
function than the patients’ in all the other groups. This finding
has important implications for patient management and should
be confirmed in a prospective, randomized study.
Patients with myocardial viability who were treated medi-
cally had a high mortality. Viable myocardium in patients with
severe CAD exists in a precarious state and is prone to
ischemia, infarction and a further decline in LV function
(6,23,33). Williams et al. (33) reported findings in 108 patients
with LV dysfunction who were medically treated. The risk of
adverse cardiac events was higher in patients with ischemia or
viability during DE compared with those without ischemia or
viability. In contrast, in our study, mortality was high in
medically treated patients both with and without myocardial
viability and was predicted by known prognostic variables—
namely, age and LV function. This difference may, in part, be
related to inclusion of ischemic events and late revasculariza-
tion as end points in the study of Williams et al. (33). The
finding of high mortality in our medically treated patients with
a LVEF ,35% is supported by several large studies (1–3).
Comparison with previous studies. Few data are available
regarding the impact of myocardial viability on clinical out-
come and prognosis. Nesto et al. (36) were the first to report
improved survival with revascularization in patients who dem-
onstrated preoperative inotropic reserve, assessed by epineph-
rine infusion or as post extrasystolic potentiation. The current
data on myocardial viability and prognosis are largely confined
to small, retrospective studies that utilized positron emission
tomography or thallium scintigraphy for viability assessment.
In a study of 36 patients, only those with preoperative evidence
of myocardial viability by positron emission tomography
showed improvement in heart failure after bypass surgery (37).
DiCarli et al. (38) showed that revascularization was associated
with improved survival in patients with evidence of myocardial
viability by positron emission tomography. Lee et al. (13)
retrospectively studied 129 patients with LV dysfunction who
underwent positron emission tomography. Seventy patients
showed evidence of viability and 49 of these were revascular-
ized. On follow-up, ischemic events occurred in 48% of
patients not revascularized compared with 8% of those revas-
cularized. However, the study did not show a difference in
survival after revascularization between patients with and
without viability. Eitzman et al. (14) studied 82 patients with
CAD and LV dysfunction using positron emission tomography.
Among those with myocardial viability, the incidence of car-
diac events was 12% in patients who were revascularized and
50% in those not revascularized. Recently, a “viability index”
derived from thallium uptake during rest redistribution scin-
tigraphy was shown to predict cardiac event-free survival after
bypass surgery in 70 patients with LV dysfunction (15).
Our study adds significantly to these reports in several
respects. This is the first study to demonstrate improved
survival with revascularization in patients with CAD and LV
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dysfunction who demonstrate myocardial viability as assessed
by DE. We studied a large number of patients and used
all-cause mortality as the end point. We compared survival in
patients treated both medically and with revascularization.
Most previous studies on myocardial viability have included
patients with moderate LV dysfunction. Assessment of viability
in such patients is not important because the operative risk is
low and the benefit of revascularization is well demonstrated.
In contrast, we only studied patients with severe LV dysfunc-
tion (LVEF #35%). It is in this subgroup of patients that
evaluation of myocardial viability is important to identify those
likely to benefit from revascularization.
Study limitations. There are several important limitations
of our study. The decision to revascularize was not random-
ized, and in most cases the results of DE were available to the
patients’ physicians. Although ideally this study should have
been done with random assignment of treatment, it is nearly
impossible at present to randomize patients with evidence of
“myocardial viability” to medical therapy. However, patients in
the four groups were well matched regarding baseline charac-
teristics as well as prevalence of three-vessel CAD and severity
of LV dysfunction. Patients in group III (no myocardial
viability, revascularized) were somewhat younger, with a
slightly higher LVEF. Despite these characteristics, patients in
group III had a higher mortality compared with group I
(myocardial viability, revascularized). Although the echocar-
diographic studies were interpreted without blinding to clinical
data, the interpretation was performed before intervention and
thus was blinded to outcome.
The echocardiograms were interpreted locally at each cen-
ter by multiple readers. We did not study the interobserver
variability of the readers who interpreted the echocardiograms.
All centers that participated in this study have extensive
experience in performance and interpretation of DE. The
studies were read by experts who consistently interpret large
volumes of stress echocardiograms. Single-center interob-
server variability data, showing good concordance, have been
published by many investigators, including the authors of this
report (10,16,39). Interinstitutional variability in interpretation
of dobutamine echocardiograms has also been previously
published (40). That study had several limitations, including
use of videotape rather than digital images, re-recording of
images and even inclusion of patients with nonvisualization of
all segments in one or more vascular territories. Despite these
limitations, agreement between observers was over 70%. We
also based the classification of dobutamine echocardiograms
on change in wall motion rather than absolute wall motion
score; the former is associated with greater interobserver
agreement (41). Use of local test interpretation also offers the
advantage of increasing the general applicability of the study.
Our data represent real clinical practice in major medical
centers. A consistent bias in any direction is unlikely because
interpretation of dobutamine echocardiograms was done be-
fore any follow-up. There were differences in DE protocol
between centers. In ;20% of patients, high dose dobutamine
was not given. Because of this some patients who may have
demonstrated ischemia at a high dose could have been mis-
classified as lacking myocardial viability. An ischemia-only
response was uncommon in our study group. Among patients
who underwent high dose DE, only 7% of visualized segments
showed an ischemia-only response. Thus, it is unlikely that we
missed an ischemia-only response in a large number of patients
who only underwent a low dose study. Furthermore, we
repeated the analysis, defining myocardial viability as improve-
ment at a low dose, regardless of a high dose response. Survival
remained significantly higher in group I compared with the
other groups (7% vs. 18%, p 5 0.05 by the log-rank test).
Follow-up data could not be obtained in 10% of patients. The
patients lost to follow-up were similarly distributed in the four
groups (7% in group I, 11% group II, 3% group III and 13%
in group IV; p 5 0.2).
Conclusions. Our data suggest that patients with CAD and
severe LV dysfunction should undergo testing for myocardial
viability. Those with viability should be considered for revas-
cularization. Patients without viability are unlikely to benefit
from revascularization, and transplantation may be a better
alternative in such cases. These findings should be confirmed in
a prospective, randomized study.
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